After the FDA granted Merck's Ebola vaccine candidate V920 priority review status, the company announced plans to manufacture 650,000 more doses over the next 6 to 18 months in order to meet the current demand for its Ebola vaccine being used in the Democratic Republic of Congo​ to combat an ongoing outbreak. Source: Healio 17/9/2019